Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;202(4):441-448.
doi: 10.1007/s00408-024-00715-0. Epub 2024 Jul 15.

Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry

Femke Demolder  1 , Eef Vanderhelst  2 , Sylvia Verbanck  2 , Florence Schleich  3 , Renaud Louis  4 , Guy Brusselle  5 , Carine Sohy  6 , Alain Michils  7 , Rudi Peché  8 , Charles Pilette  9 , Shane Hanon  2
Affiliations
Free article

Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry

Femke Demolder et al. Lung. 2024 Aug.
Free article

Abstract

Background: Nasal polyposis (NP) is a comorbidity of type 2 severe asthma (SA) which could influence response to SA biologics.

Methods: We evaluated (super-) response in SA patients with (NP +) and without NP (NP-) enrolled in the Belgian Severe Asthma Registry (BSAR).

Results: 914 patients, of whom 31% NP + , were included. At enrollment, NP + patients had higher annual exacerbation rates, higher number of emergency room visits and more elevated type 2 biomarkers. In the longitudinal subanalysis of 104 patients, both groups had significant and similar asthma responses to asthma biologics, except for a greater increase in FEV1 in the NP + group. Super-response was achieved in 33 patients (32%), irrespective of NP status or type of biologic.

Conclusion: In conclusion, both NP + and NP - patients had positive treatment responses, with some able to achieve super-response. In SA patients with NP, a greater FEV1 improvement as compared to SA patients without NP was observed.

Keywords: Biologics; Nasal polyposis; Severe asthma; Super-response.

PubMed Disclaimer

References

    1. Canonica GW, Malvezzi L, Blasi F et al (2020) Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med 166:105947. https://doi.org/10.1016/j.rmed.2020.105947 - DOI - PubMed
    1. Brusselle GG, Koppelman GH (2022) Biologic therapies for severe asthma. N Engl J Med 386(2):157–171. https://doi.org/10.1056/NEJMra2032506 - DOI - PubMed
    1. Schleich F, Moermans C, Seidel L et al (2023) Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction - PROMISE. ERJ Open Res 9(6):00383–02023. https://doi.org/10.1183/23120541.00383-2023 - DOI - PubMed - PMC
    1. Wautlet A, Bachert C, Desrosiers M, Hellings PW, Peters AT (2023) The management of chronic rhinosinusitis with nasal polyps (CRSwNP) with biologics. J Allergy Clin Immunol Pract 11(9):2642–2651. https://doi.org/10.1016/j.jaip.2023.04.054 - DOI - PubMed
    1. Kolkhir P, Akdis CA, Akdis M et al (2023) Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov 22(9):743–767. https://doi.org/10.1038/s41573-023-00750-1 - DOI - PubMed

Publication types

MeSH terms